Home>Topics>Companies>Beckman Coulter

Beckman Coulter BEC

  1. All
  2. Commentary
  3. Headlines
    1. Alere's Cost Cuts Remain on Track Following Health Management Divestiture


      Tue, 10 Feb 2015

      contributed to strong cardiometabolic sales in China and India. The company also mitigated supply constraints for the Beckman Coulter BNP product, contributing to 3% growth in infectious disease. Despite Alere’s success in Asia, ex-U.S

    2. Alere's Health Management Divestiture Is Step in Right Direction


      Tue, 28 Oct 2014

      fell 1% on an organic basis due to lower pain management revenue from the toxicology business and lower sales of Beckman Coulter BNP tests in light of supply constraints. As expected, health information solutions revenue fell 7%, probably

    3. Lower Reimbursement and Product Recalls Weigh on Alere's 2Q Results


      Mon, 4 Aug 2014

      due to lower utilization, as well as product returns for the INR business and a second-quarter recall of certain Beckman Coulter Triage BNP Tests. The company captured strong growth in India and Africa, though this was partially offset by weak

    4. Danaher Offers Mixed Second-Quarter Results, but Announces an Acquisition as a Peace Offering


      Thu, 17 Jul 2014

      business. We think the company’s integration of Beckman Coulter is beginning to pay dividends by enhancing margins while ..... Adding to its life science and diagnostics business, Beckman Coulter acquired Siemens’s Microbiology business for

    5. Siemens to sell microbiology unit to US-based Danaher


      Thu, 17 Jul 2014

      FRANKFURT, July 17 (Reuters) - German engineering group Siemens agreed to sell its clinical microbiology business to Beckman Coulter , a subsidiary of Danaher Corp, as part of a restructuring plan...

    6. J&J's $4.15 Billion Diagnostics Sale Slightly Improves Competitive Position


      Thu, 16 Jan 2014

      t expect any changes to our fair value estimate. (As a reference point, Danaher acquired diagnostics company Beckman Coulter in 2011 for approximately 2 times sales.) We view the divestiture as slightly strengthening Johnson & Johnson

    7. Danaher Delivers Strong Fourth-Quarter Earnings and Cash Flow


      Thu, 18 Apr 2013

      2011 in the life sciences also stands out as Danaher continues to drive operating improvements from recently acquired Beckman Coulter and AB Sciex. During 2012, Danaher generated $3 billion of free cash flow, a 25% improvement versus the prior

    8. Danaher's Third Quarter Below Expectations, Cash Flow Remains Strong


      Thu, 18 Oct 2012

      in the prior year, after accounting for charges related to the Beckman Coulter acquisition. Our primary concerns for the portfolio reside in the ..... operations is nearly $3.4 billion, driven by strong performance at Beckman Coulter .

    9. Core Revenue Growth Continues to Weaken for Danaher in First Quarter


      Thu, 19 Apr 2012

      think the firm needs a bit more time to drive synergies from Beckman and Esko Artwork. Additionally, the recently announced acquisition ..... onto core margin, but there is only one more quarter that Beckman will not be in the comparisons, and we think the firm may

    10. Internal Revenue Growth Slows in 4Q for Danaher; Beckman Making Strides


      Tue, 31 Jan 2012

      versus the prior year. The addition of Beckman Coulter helped lift revenue another 33%. Beckman 's integration is going well by management ..... within the firm. The company also noted that Beckman 's working capital has yet to really feel

    « Prev12345Next »
    Content Partners